X

On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination Management Services Inc., (EMSI) has gone out of business. Because of this, unfortunately, all future Lemtrada Home Phlebotomy (lab draw) visits from EMSI have been cancelled. Patient safety is Sanofi Genzyme’s #1 priority and we are working to provide an alternative phlebotomy solution as well as coordinate alternative testing options for your next monthly lab tests. If you have any questions related to this announcement, please contact your healthcare provider or your One to One Nurse at 1-855-557-2483.

MAT-US-2015317

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

Making Your Decision

Choosing to start LEMTRADA infusion treatment for relapsing MS

There’s a lot to consider before starting or switching your relapsing MS treatment. Before you can begin treatment with LEMTRADA, you’ll need to have an honest discussion with your healthcare provider about how you are doing on your current treatment, and if your relapsing MS goals are being met.

Some key topics to discuss with your healthcare provider:

  • How often you’re experiencing relapses
  • If you’re seeing signs of disability progression
  • What you think about the potential benefits and possible risks of LEMTRADA
  • Other factors to consider before starting LEMTRADA, such as:
    • your health history
    • prior relapsing MS treatments

For more topics to talk about at your next appointment, you can download the Discussion Guide.

There are other people to include when making a treatment decision—your family and close friends.
Having the support of those around you can help make your decision easier.

Some key topics to discuss with your family and friends:

  • How does relapsing MS affect those around me?
  • Has my relapsing MS disability become more noticeable?
  • Do you think the potential benefits of LEMTRADA outweigh the possible risks?
  • Will you be able to help support me throughout my treatment?

Starting the LEMTRADA treatment process

Once you and your healthcare provider decide to make LEMTRADA your next relapsing MS treatment, there are some important steps to take before you can begin.

Complete REMS enrollment with your doctor to get started on LEMTRADA
REMS Enrollment

You will fill out the required Risk Evaluation and Mitigation Strategy (REMS) paperwork at your healthcare provider’s office. Soon after, you will receive a phone call from your dedicated MS One to One® nurse to answer your questions and discuss next steps.

MS One to One will help with insurance verification
Insurance Approval

Your MS One to One nurse will help you with insurance approval and may provide you with financial support resources for your LEMTRADA treatment.

Your doctor will perform tests and may recommend vaccinations before you start LEMTRADA therapy
Tests and Vaccinations

Your healthcare provider will test you for certain medical conditions and may recommend vaccinations that you’ll need to complete at least 6 weeks before your treatment start date.

Relapsing MS doctor discussion guide download

HEALTHCARE PROVIDER
DISCUSSION GUIDE

Download this guide to prepare for a conversation about treatment.

Jennifer
LEMTRADA
PATIENT

I’ve focused on
the treatment
that will be

Most
effective
for me.

See what led patients to talk to their doctors about LEMTRADA.

Important Safety Information See More

LEMTRADA can cause serious side effects including serious autoimmune problems. Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include: